Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
2006 · British Journal of Cancer · 173 citations
https://doi.org/10.1038/sj.bjc.6603171
N
Nancy Lewis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
94
Papers
4.1K
Citations
32
h-index
52
i10-index
Nancy Lewis is an academic researcher from Mercy Clinic Neurology. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & interferon and immune responses. The author has an h-index of 32, co-authored 80 publications.
ORCID: 0000-0002-6710-6999Papers by this author
worksWhat implementation interventions increase cancer screening rates? a systematic review
2011 · Implementation Science · 150 citations
https://doi.org/10.1186/1748-5908-6-111
Effective interventions to facilitate the uptake of breast, cervical and colorectal cancer screening: an implementation guideline
2011 · Implementation Science · 74 citations
https://doi.org/10.1186/1748-5908-6-112
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
2012 · Investigational New Drugs · 44 citations
https://doi.org/10.1007/s10637-012-9890-y
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
2013 · BMC Cancer · 42 citations
https://doi.org/10.1186/1471-2407-13-20
Aggressive Digital Papillary Adenocarcinoma: A Meta-Analysis of the Presentation, Treatment, and Outcomes of a Rare Hand Tumor
2025 · Hand · 0 citations
https://doi.org/10.1177/15589447241308612
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat